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Several prophylactic medications for opportunistic or recurrent infections are used in human immunode-
ficiency virus-infected individuals. Essential to the efficacy evaluation of these agents is the accurate reporting
of medication compliance. We hypothesized that poor patient compliance with thrice-weekly fluconazole
prophylaxis would correlate with the occurrence of clinical events. Fluconazole compliance was monitored
electronically by using the Medication Event Monitoring Systems with 19 women receiving fluconazole at 50 mg
thrice weekly for prophylaxis of recurrent mucocutaneous candidiasis. During 202 patient-months of follow-up,
eight breakthrough episodes of mucocutaneous candidiasis developed in four women; compliance data were
available for seven of these episodes. At 6 months of therapy, more women with greater than or equal to 80%
compliance were disease free compared with women with less than 80% compliance (P < 0.05; the Fisher exact
test). These data suggest that documentation of medication compliance is essential in studies of chronic
prophylaxis in human immunodeficiency virus-infected patients to properly evaluate drug efficacy and to avoid
erroneous conclusions concerning drug failure.
Noncompliance with drug therapy may lead to the increased
use of health care resources and reduced quality of life. It has
been reported that 11 to 28% of emergency room visits or
hospital admissions are due to medication noncompliance (4,
7, 13). One meta-analysis estimated that the annual cost of
medication noncompliance is approximately $8.5 billion (17).
Several methods for the assessment of medication compliance
have been used in clinical settings as well as in clinical trials.
These methods include monitoring of the level of the drug in
the patient’s blood, measurement of drug excretion in urine,
pill counts, patient questionnaires, observation of therapeutic
outcome, and the presence of side effects (5). All of these
methods have certain important limitations. For example, pill
counts may be altered by patients and monitoring of drug
levels in blood and urinary excretion studies are inconvenient,
nonquantitative, and expensive. Single measurements of drug
concentrations in serum are subject to the need for accurate
dosing histories and assumptions concerning steady-state con-
ditions; hence, these measures are not precise assessments of
drug compliance patterns, particularly compliance with drugs
with long half-lives. The Medication Event Monitoring Sys-
tems (MEMS) are normal-appearing prescription vials with
caps containing microprocessors which record the date and
time of vial opening. Studies have shown that MEMS can
assess patient compliance with certain medications (3, 14). The
advantage of MEMS compared with other forms of compli-
ance monitoring is the ability to quantitatively assess compli-
ance over prolonged periods of treatment. Other methods,
such as determination of drug levels in serum, only measure
compliance since the preceding dosing interval or the last few
days prior to testing of the drug level in serum. MEMS have
the additional advantage of reporting the length of time be-
tween scheduled doses (14). With the increasing rise in the
number of women with human immunodeficiency virus (HIV)
infection, an understanding of the unique health care needs of
women and their obstacles to the provision of health care is
essential, including assessment of medication compliance. Fur-
thermore, medication noncompliance can obfuscate the assess-
ment of the efficacy of a prophylactic medication. The purpose
of the study described here was to electronically monitor
thrice-weekly fluconazole dosing events during a clinical trial
with HIV-infected women in order to assess the influence of
compliance on clinical events.
MATERIALS AND METHODS
Trial design. A multicenter, randomized, cross-over study was conducted with
HIV-infected women with CD41 counts of less than 500 cells per mm3 to
determine if fluconazole prophylaxis is effective for the prevention of vaginal,
oropharyngeal, and esophageal candidiases; the preliminary results have been
reported elsewhere (6). HIV-infected women with CD41 counts of less than 500
cells per mm3, over 18 years of age, without a history of systemic fungal disease,
without current mucosal fungal infection, and with transaminase levels less than
five times the upper limit of normal qualified for randomization. Informed
consent was obtained from the patients, and the guidelines for human experi-
mentation of the U.S. Department of Health and Human Services and The
Miriam Hospital and Rhode Island Hospital, Providence, R.I., were followed in
the conduct of the study. Women were randomized to receive either fluconazole
at 50 mg on a Monday, Wednesday, and Friday or to receive no treatment but to
undergo regular observation. A history was taken and a symptom-oriented phys-
ical examination was performed every 3 months for all women enrolled in the
study. If women were symptomatic for mucocutaneous candidiasis, a potassium
hydroxide preparation of the potentially infected site was completed. If a break-
through episode developed while a woman was noncompliant with fluconazole,
the patient was treated with topical antifungal agents; if a breakthrough episode
developed while a women was compliant with thrice-weekly fluconazole, the
patient was treated with a higher daily dose of fluconazole.
Compliance monitoring. MEMS-3 (Aprex Corporation, Fremont, Calif.) was
used to monitor patient compliance. At the time of entry into the trial, patients
randomized to receive fluconazole were dispensed a 3-month supply of flucon-
azole in a MEMS vial. The patients were informed that the cap contained a
computer chip for the purpose of recording the timing of dosing, but it was
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stressed that dosing readings would not threaten their status in the study. Pa-
tients were instructed to keep the fluconazole in the MEMS vial and not to
remove the drug and put it in another container. At every 3-month follow-up
visit, a clinical pharmacist transferred the information from the MEMS cap to a
laptop computer using the appropriate software, and an additional 3-month
supply of fluconazole was dispensed in the same MEMS vial.
Data analysis.Medication events were quantitatively calculated per week, with
100% compliance considered three vial openings per week. Qualitative compli-
ance (i.e., doses taken on Monday, Wednesday, and Friday, as prescribed) was
similar to the quantitative compliance and was not incorporated into the present
analysis. A quantitative value of greater than 80% compliance was classified as
good compliance, as previously defined by others (1, 15). Failure of therapy was
concluded when a patient either developed a documented episode of mucocu-
taneous candidiasis or dropped out of the study. Treatment failure after 6
months of therapy was compared in women with greater than 80% compliance
versus those with less than 80% compliance by Kaplan-Meier analysis and the
Fisher exact test (9, 11, 16, 17).
RESULTS
Electronic compliance data were available for 19 patients
monitored for 202 patient-months. Table 1 provides the char-
acteristics of the patients. Most women were Caucasian and
identified intravenous drug use (IVDU) as one risk factor for
HIV transmission. A minority of women were diagnosed with
AIDS. The reasons for patient attrition from the study in-
cluded IVDU, pregnancy, lack of desire to take another med-
ication, medication side effects, breakthrough infections, or
death.
Eight episodes of mucocutaneous candidiasis occurred in
four patients during the period of monitoring with MEMS,
with compliance information available for seven of these epi-
sodes. Figure 1 displays the biweekly compliance by the 15
women without breakthrough episodes and each of the 4
women who developed breakthrough episodes.
Patient 1. Two episodes of documented vaginal candidiasis
occurred in weeks 20 and 24 in patient 1. In both episodes, a
period of significant noncompliance was observed prior to or at
the time of breakthrough.
Patient 2. Patient 2 experienced a symptomatic, KOH-pos-
itive episode of vaginal candidiasis after 6 weeks of fluconazole
prophylaxis. The patient appeared to be compliant with the
regimen by MEMS recordings. Despite poor compliance after
this single episode, no further episodes of vaginal candidiasis
occurred in this patient. This patient’s CD41 count remained
at between 100 and 200 cells per mm3 during the study period.
Patient 3. Esophageal candidiasis developed in patient 3
after 23 months of fluconazole prophylaxis. The pattern of
fluconazole use in this patient over the preceding 3 months
showed erratic drug administration. Furthermore, this pa-
tient’s most recent CD41 count 10 months before the candidal
infection was 70 cells per mm3.
Patient 4. Three episodes of mucocutaneous candidiasis oc-
curred in patient 4 during prophylaxis. Two breakthrough ep-
isodes appeared to be related to noncompliance. The third
episode in this patient occurred while the patient was compli-
ant, but her CD41 count had recently dropped below 50 cells
per mm3.
Analysis of compliance. Compliance over the entire study
period was analyzed by grouping the women according to
whether or not they were greater than or equal to 80% com-
pliant. Figure 2 shows that the time to treatment failure was
significantly shorter for women with less than 80% compliance
compared with that for women with greater than or equal to
80% compliance. The median time to the first breakthrough
infection was 19 weeks. At 6 months of treatment, significantly
more women with less than 80% compliance had failed treat-
ment than women with greater than 80% compliance (P ,
0.05; the Fisher exact test).
DISCUSSION
In the present study of 19 women receiving fluconazole
prophylaxis, eight breakthrough episodes of mucocutaneous
candidiasis occurred in four women. Because of the low num-
ber of breakthrough episodes, we cannot definitely associate
noncompliance with breakthrough episodes. In some study
patients (e.g., patient 2), there were no breakthrough episodes
during prolonged periods of noncompliance. While noncom-
pliance immediately preceding a breakthrough event did not
occur in every instance, it does appear that women with an
overall higher level of compliance (greater than 80%) experi-
enced a longer disease-free period than women with an overall
lower level of compliance (less than 80%). Advanced immu-
nosuppression, as suggested by markedly decreased CD41
counts, may have predisposed even a compliant patient to a
breakthrough infection. Although medication resistance could
have contributed to the breakthrough episodes in some of
these women, this hypothesis cannot be confirmed since the
organisms isolated were not tested for their susceptibilities to
fluconazole.
Assurance of medication compliance and the degree of med-
ication compliance are crucial for the proper assessment of the
efficacies of new treatment approaches. In studies of oral tri-
methoprim-sulfamethoxazole in the prevention of infection in
neutropenic patients, good medication compliance was associ-
ated with a significant reduction in the incidence of fever or
infection compared with the incidence in placebo-treated pa-
tients (12). When both compliant and noncompliant patients
were combined, there was no significant difference in infection
rates between placebo and trimethoprim-sulfamethoxazole-
TABLE 1. Demographic data for 15 women without and 4 women
with resulting episodes during fluconazole prophylaxisa
Characteristic
Value
15 women without
breakthroughs
4 women with
breakthroughs
Age
Median 30 37.5
Range 24–45 28–40
Race (no. [%])
Caucasian 12 (80) 2 (50)
Hispanic 3 (20) 2 (50)
Transmission risk group (no. [%])
IVDU or heterosexual contact 7 (47) 2 (50)
IVDU (no. [%]) 5 (33) 2 (50)
Heterosexual contact (no. [%]) 2 (13) 0 (0)
IVDU or contact with blood prod-
ucts (no. [%])
1 (7) 0 (0)
Duration of HIV seropositivity (yr)
Median 3 3
Range 1–6 3–6
Diagnosis of AIDS (no. [%]) 1 (7) 1 (25)
Prophylactic antibiotic use (co-tri-
moxazole or dapsone) (no. [%])
3 (20) 2 (50)
Antiretroviral therapy (no. [%]) 14 (93) 4 (100)
Prior episodes of candidiasis (no. [%]) 11 (73) 4 (100)
a No difference between groups by Fisher’s exact test.
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FIG. 1. Average number of openings in a 2-week period recorded by MEMS for study patients on thrice-weekly fluconazole therapy. Arrows indicate when
breakthrough events occurred. Dashed lines indicate 100% compliance (three recorded openings per week).
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treated patients. For prophylactic medications taken for a pro-
longed period of time, consistent therapy correlates with a
favorable outcome. In patients receiving isoniazid prophylaxis
for the prevention of tuberculosis reactivation, compliance
tends to decrease over time, with the duration of prophylaxis
associated with medication benefit (2). Compared with pla-
cebo, isoniazid prophylaxis for 12 weeks caused only a slight
reduction in reactivation, whereas compliance for 24 weeks
was associated with a 65% reduction in reactivation. A full year
of treatment resulted in a 75% reduction in reactivation. In the
four women developing mucocutaneous candidal infections
that we describe, erratic fluconazole dosing was displayed over
time in each patient.
Several logistic and technical problems occurred during the
study that we report here. MEMS data were not available for
a few patients because the patient lost the vial or broke the cap
when she accidentally dropped it. Spurious noncompliance
readings occurred for a few women who reported removal of
several medication doses from the vial all at once for travel
purposes.
The use of MEMS in the present study required coordina-
tion between the study nurses and the clinical pharmacist.
Good communication was necessary, as was flexibility in deal-
ing with women who would show up for a refill without a
scheduled appointment and with women who would not show
up for scheduled appointments.
Most women were very enthusiastic about seeing the com-
puter display of compliance. Patients often wanted to know
their medication compliance rates over the previous 3-month
period, and many were encouraged when they saw that they
had been compliant. In addition, during refill appointments
with MEMS readings, the patients would often explain why the
medication dosages were missed on certain days, which was
helpful in gathering accurate dosing histories.
We believe that the present study emphasizes the impor-
tance of tracking individual patient compliance during a clin-
ical trial, specifically with a medication not dosed every day.
Because breakthrough episodes of mucocutaneous candidiasis
have been attributed to medication failure or resistance devel-
opment, it is essential to confirm patient compliance in these
situations (10). In addition to erroneously assuming drug fail-
ure, noncompliance during clinical trials can lead to overesti-
mation of the optimal dose of a medication (8). In the present
study, electronic compliance monitoring provided data on both
overall compliance and the specific patterns of drug use, which
were necessary to determine an association with breakthrough
infections. Implementation of strategies to enhance medica-
tion compliance may improve patient outcomes as a result of
the use of prophylaxis in this population and reduce the cost of
care for these patients.
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